Analyze Diet
World journal of microbiology & biotechnology2023; 39(9); 231; doi: 10.1007/s11274-023-03677-2

Antimicrobial susceptibility of Rhodococcus equi strains isolated from foals in Chile.

Abstract: Rhodococcus equi is responsible for foal pneumonia worldwide, with a significant economic impact on the production and breeding of horses. In Chile, the first case was reported in 2000, and since then, its incidence has been increasing. Distinctive characteristics of R. equi as an intracellular pathogen in macrophages, emergence of virulence plasmids encoding surface lipoprotein antigens, and appearance of antibiotic resistance against macrolides and rifampicin have significantly complicated the treatment of R. equi pneumonia in foals. Therefore, in vitro susceptibility studies of first-line and newer antibiotics against R. equi are the first step to establishing effective treatments and optimizing new therapeutic options. The aim of the present study is to determine the susceptibility profile of fourteen strains of R. equi isolated from foals in Chile to several antibiotics of the macrolide group including azithromycin, amikacin, tildipirosin and gamithromycin as well as others such as rifampicin, doxycycline and ceftiofur. Identification of R. equi in collected isolates from foals in Chile has been performed by CAMP test and PCR based on detecting of the gene encoding the 16 S rRNA. The presence of genes encoding virulence plasmids was also determined using PCR. Results obtained have demonstrated presence of virulent R. equi strains in Chile. In vitro susceptibility pattern to different antibiotics has shown better results for doxycycline and rifampicin similar to previous studies performed. Current macrolides have been evaluated in order to consider alternative treatment options in a context of emerging resistance to classic macrolides and rifampicin, obtaining better results with gamithromycin (MIC range of 0.125 to 128 mg/ml) than with tildipirosin (MIC range of 16 to 128 mg/ml). An adequate diagnosis of bacterial susceptibility based on antibiograms is necessary to treat the Rhodococcus equi infection in foals.
Publication Date: 2023-06-22 PubMed ID: 37347336PubMed Central: PMC10287571DOI: 10.1007/s11274-023-03677-2Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research study seeks to understand the resistance patterns of Rhodococcus equi strains obtained from foals in Chile to various antibiotics, with a focus on first-line and novel alternatives. The researchers found that current macrolides could provide potential alternative treatments due to the growing resistances to traditional macrolides and rifampicin.

Introduction and Background

  • The research focuses on Rhodococcus equi, a bacterium that causes pneumonia in foals; a problem that is global, with an increasing incidence in Chile.
  • Due to the bacterium’s unique characteristics, such as being an intracellular pathogen in macrophages, harboring virulence plasmids, and its growing resistance to macrolides and rifampicin, treating R. equi pneumonia has become increasingly difficult.
  • To counter these challenges, the researchers conducted in vitro susceptibility studies on newer antibiotics, positioning this as the first step in discovering effective treatments and new therapeutic options.

Methodology

  • The team collected and then isolated 14 different strains of R. equi from foals in Chile.
  • The researchers identified these strains using a combination of the CAMP test and PCR, with the latter targeting the gene encoding the 16S rRNA.
  • The team also used PCR to discern whether the bacteria had genes encoding for virulence plasmids.

Results

  • The tests conducted revealed the presence of virulent R. equi strains in Chilean foals
  • The bacterial strains’ susceptibility patterns to different antibiotics were similar to the patterns found in past studies, with doxycycline and rifampicin showing good results.
  • The team also assessed the efficacy of current macrolides as alternative treatments. The best results were with gamithromycin (MIC range of 0.125 to 128 mg/ml), whereas tildipirosin exhibited a less favorable MIC range of 16 to 128 mg/ml.

Conclusion

  • For effective treatment of R. equi infections in foals, an accurate diagnosis of bacterial susceptibility based on antibiograms is critical.
  • The study’s findings underscore the necessity of evaluating both first-line and alternative antibiotics due to the growing resistance to traditional antibiotics.

Cite This Article

APA
Zúñiga MP, Badillo E, Abalos P, Valencia ED, Marín P, Escudero E, Galecio JS. (2023). Antimicrobial susceptibility of Rhodococcus equi strains isolated from foals in Chile. World J Microbiol Biotechnol, 39(9), 231. https://doi.org/10.1007/s11274-023-03677-2

Publication

ISSN: 1573-0972
NlmUniqueID: 9012472
Country: Germany
Language: English
Volume: 39
Issue: 9
Pages: 231
PII: 231

Researcher Affiliations

Zúñiga, María Paz
  • Facultad de Agronomía y Veterinaria, Universidad Nacional de Rio Cuarto, Córdova, Argentina.
  • Escuela de Medicina Veterinaria, Facultad de Ciencias, Universidad Mayor, Santiago de Chile, Chile.
Badillo, Elena
  • Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Murcia, 30100, Spain.
Abalos, Pedro
  • Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, La Pintana, 8820808, Chile.
Valencia, Eduardo David
  • Instituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, EC, 170157, Ecuador.
Marín, Pedro
  • Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Murcia, 30100, Spain.
Escudero, Elisa
  • Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Murcia, 30100, Spain.
Galecio, Juan Sebastian
  • Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Murcia, 30100, Spain. jsgalecio@um.es.
  • Colegio de Ciencias de la Salud, Escuela de Medicina Veterinaria, Universidad San Francisco de Quito, Quito, EC, 170157, Ecuador. jsgalecio@um.es.

MeSH Terms

  • Horses
  • Animals
  • Rifampin / pharmacology
  • Doxycycline
  • Rhodococcus equi / genetics
  • Chile
  • Macrolides
  • Anti-Bacterial Agents / pharmacology

Conflict of Interest Statement

None of the authors have any financial or personal relationships that could inappropriately influence or bias the contents of the paper.

References

This article includes 53 references
  1. Berghaus LJ, Giguère S, Sturgill TL, Bade D, Malinski TJ, Huang R. Plasma pharmacokinetics, pulmonary distribution, and in vitro activity of gamithromycin in foals.. J Vet Pharmacol Ther 2012 Feb;35(1):59-66.
  2. Berghaus LJ, Giguère S, Guldbech K, Warner E, Ugorji U, Berghaus RD. Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.. J Clin Microbiol 2015 Jan;53(1):314-8.
    doi: 10.1128/JCM.02673-14pmc: PMC4290945pubmed: 25378571google scholar: lookup
  3. Berlin S, Spieckermann L, Oswald S, Keiser M, Lumpe S, Ullrich A, Grube M, Hasan M, Venner M, Siegmund W. Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals.. Mol Pharm 2016 Mar 7;13(3):1089-99.
  4. Berlin S, Randow T, Scheuch E, Grube M, Venner M, Siegmund W. Pharmacokinetics and pulmonary distribution of gamithromycin after intravenous administration in foals.. J Vet Pharmacol Ther 2017 Aug;40(4):406-410.
    doi: 10.1111/jvp.12402pubmed: 28317153google scholar: lookup
  5. Burton AJ, Giguère S, Sturgill TL, Berghaus LJ, Slovis NM, Whitman JL, Levering C, Kuskie KR, Cohen ND. Macrolide- and rifampin-resistant Rhodococcus equi on a horse breeding farm, Kentucky, USA.. Emerg Infect Dis 2013 Feb;19(2):282-5.
    doi: 10.3201/eid1902.121210pmc: PMC3559061pubmed: 23347878google scholar: lookup
  6. Burton AJ, Giguère S, Sturgill TL, Berghaus LJ, Slovis NM, Whitman JL, Levering C, Kuskie KR, Cohen ND. Macrolide- and rifampin-resistant Rhodococcus equi on a horse breeding farm, Kentucky, USA.. Emerg Infect Dis 2013 Feb;19(2):282-5.
    doi: 10.3201/eid1902.121210pmc: PMC3559061pubmed: 23347878google scholar: lookup
  7. Burton AJ, Giguère S, Berghaus LJ, Hondalus MK. Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice.. Antimicrob Agents Chemother 2015;59(6):3633-6.
    doi: 10.1128/AAC.04941-14pmc: PMC4432177pubmed: 25824218google scholar: lookup
  8. Byrne BA, Prescott JF, Palmer GH, Takai S, Nicholson VM, Alperin DC, Hines SA. Virulence plasmid of Rhodococcus equi contains inducible gene family encoding secreted proteins.. Infect Immun 2001 Feb;69(2):650-6.
    doi: 10.1128/IAI.69.2.650-656.2001pmc: PMC97935pubmed: 11159951google scholar: lookup
  9. Camponovo C R, García C P. [Rhodococcus equi].. Rev Chilena Infectol 2006 Jun;23(2):155-6.
  10. Cisek AA, Rzewuska M, Witkowski L, Binek M. Antimicrobial resistance in Rhodococcus equi.. Acta Biochim Pol 2014;61(4):633-8.
    doi: 10.18388/abp.2014_1824pubmed: 25371917google scholar: lookup
  11. . Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically approved standard.. Clinical and Laboratory Standards Institute NCCLS document M07–A8. 8. Pennsylvania: Clinical and Laboratory Standards Institute; 2008.
  12. Cohen ND. Rhodococcus equi foal pneumonia.. Vet Clin North Am Equine Pract 2014 Dec;30(3):609-22.
    doi: 10.1016/j.cveq.2014.08.010pubmed: 25282322google scholar: lookup
  13. Davis JL, Gardner SY, Jones SL, Schwabenton BA, Papich MG. Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytes.. J Vet Pharmacol Ther 2002 Apr;25(2):99-104.
  14. Erol E, Locke S, Saied A, Cruz Penn MJ, Smith J, Fortner J, Carter C. Antimicrobial susceptibility patterns of Rhodococcus equi from necropsied foals with rhodococcosis.. Vet Microbiol 2020 Mar;242:108568.
    doi: 10.1016/j.vetmic.2019.108568pubmed: 32122582google scholar: lookup
  15. Fenton CS, Buckley TC. Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007-2014.. Ir Vet J 2015;68:23.
    doi: 10.1186/s13620-015-0051-4pmc: PMC4594895pubmed: 26445669google scholar: lookup
  16. Franco-Ayala MS, Oliver-Espinosa OJ. Enfermedades de los potros neonatos y su epidemiología: una revisión.. Rev Med Vet (29), 91–105.
  17. Galecio JS, Escudero E, Badillo E, Marín P. Pharmacokinetics of tildipirosin in horses after intravenous and intramuscular administration and its potential muscle damage.. Res Vet Sci 2022 Dec 20;152:20-25.
    doi: 10.1016/j.rvsc.2022.06.033pubmed: 35908422google scholar: lookup
  18. Giguère S, Jacks S, Roberts GD, Hernandez J, Long MT, Ellis C. Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia.. J Vet Intern Med 2004 Jul-Aug;18(4):568-73.
  19. Giguère S. Therapy of Rhodococcus equi Infections in Foals.. AAEP Proc 2010;56:125–128.
  20. Giguère S. Treatment of Infections Caused by Rhodococcus equi.. Vet Clin North Am Equine Pract 2017 Apr;33(1):67-85.
    doi: 10.1016/j.cveq.2016.11.002pubmed: 28161038google scholar: lookup
  21. Giguère S, Cohen ND. Controversies in therapy of infections caused by Rhodococcus equi in foals.. Equine Vet Educ 2018;30(6):336–341.
    doi: 10.1111/eve.12870google scholar: lookup
  22. Giguère S, Lee E, Williams E, Cohen ND, Chaffin MK, Halbert N, Martens RJ, Franklin RP, Clark CC, Slovis NM. Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of R equi.. J Am Vet Med Assoc 2010 Jul 1;237(1):74-81.
    doi: 10.2460/javma.237.1.74pubmed: 20590498google scholar: lookup
  23. Giguère S, Cohen ND, Chaffin MK, Slovis NM, Hondalus MK, Hines SA, Prescott JF. Diagnosis, treatment, control, and prevention of infections caused by Rhodococcus equi in foals.. J Vet Intern Med 2011 Nov-Dec;25(6):1209-20.
  24. Giguère S, Lee EA, Guldbech KM, Berghaus LJ. In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi.. Vet Microbiol 2012 Nov 9;160(1-2):207-13.
    doi: 10.1016/j.vetmic.2012.05.031pubmed: 22704561google scholar: lookup
  25. Giguère S, Berghaus LJ, Willingham-Lane JM. Antimicrobial Resistance in Rhodococcus equi.. Microbiol Spectr 2017 Oct;5(5).
  26. Gressler LT, Petri da Silveira B, Schwab ML. Susceptibility profile of brazilian Rhodococcus equi isolates against azithromycin, clarithromycin and erythromycin.. Ciência Rural 2015;45(4):680–683.
  27. Gressler LT, Machado G, da Silveira BP, Cohen ND, Corbellini LG, Leotti VB, Diehl GN, Dos Santos LC, de Vargas AC. Prevalence of Rhodococcus equi from the nasal cavity of 1010 apparently healthy horses.. Equine Vet J 2018 Sep;50(5):667-671.
    doi: 10.1111/evj.12804pubmed: 29341220google scholar: lookup
  28. Hildebrand F, Venner M, Giguère S. Efficacy of gamithromycin for the treatment of foals with mild to moderate bronchopneumonia.. J Vet Intern Med 2015 Jan;29(1):333-8.
    doi: 10.1111/jvim.12504pmc: PMC4858060pubmed: 25619521google scholar: lookup
  29. Hondalus MK, Mosser DM. Survival and replication of Rhodococcus equi in macrophages.. Infect Immun 1994 Oct;62(10):4167-75.
  30. Jacks S, Giguère S, Gronwall PR, Brown MP, Merritt KA. Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals.. Am J Vet Res 2001 Dec;62(12):1870-5.
    doi: 10.2460/ajvr.2001.62.1870pubmed: 11763173google scholar: lookup
  31. Jacks SS, Giguère S, Nguyen A. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials.. Antimicrob Agents Chemother 2003 May;47(5):1742-5.
  32. Kalinowski M, Jarosz Ł, Grądzki Z. Assessment of Antimicrobial Susceptibility of Virulent Strains of Rhodococcus equi Isolated From Foals and Soil of Horse Breeding Farms With and Without Endemic Infections.. J Equine Vet Sci 2020 Aug;91:103114.
    doi: 10.1016/j.jevs.2020.103114pubmed: 32684259google scholar: lookup
  33. Kirkan Ş, Parin U, Yüksel Dolgun HT, Oral EO. Detection of Rhodococcus equi by PCR from foals and determination of antimicrobial susceptibility.. Turkish J Vet Anim Sci 2021;45(3):396–403.
    doi: 10.3906/vet-2011-109google scholar: lookup
  34. Krewer Cda C, Spricigo DA, de Avila Botton S, da Costa MM, Schrank I, de Vargas AC. Molecular characterization of Rhodococcus equi Isolates of horse breeding farms from an endemic region in South of Brazil by multiplex PCR.. Braz J Microbiol 2008 Jan;39(1):188-93.
  35. Le Corre S, Janes J, Slovis NM. Multiple extra-pulmonary disorders associated with Rhodococcus equi infection in a 2-month-old foal.. Equine Vet Educ 2021;33:e231–e238.
    doi: 10.1111/eve.13279google scholar: lookup
  36. Lohse JC, Paredes E, Vargas D, Takai S. Rhodococcus equi virulento aislado de potrillos Fina sangre de carrera en Chile.. Rev Investig Vet del Perú 2019;30(3):1314–1323.
  37. Martens RJ, Martens JG, Fiske RA. Rhodococcus equi foal pneumonia: pathogenesis and immunoprophylaxis.. Proc Annu Conv Am Assoc Equine Pract 1990;35:199–213.
  38. Muscatello G. Rhodococcus equi pneumonia in the foal--part 2: diagnostics, treatment and disease management.. Vet J 2012 Apr;192(1):27-33.
    doi: 10.1016/j.tvjl.2011.08.009pubmed: 22036870google scholar: lookup
  39. Nordmann P, Ronco E. In-vitro antimicrobial susceptibility of Rhodococcus equi.. J Antimicrob Chemother 1992 Apr;29(4):383-93.
    doi: 10.1093/jac/29.4.383pubmed: 1607327google scholar: lookup
  40. Paredes E, Gallego R, Canal AM. Primer caso descrito en Chile de neumonía y colitis por Rhodococcus equi en un potrillo.. Arch Med Vet 2000;32(1):101–106.
  41. Peiró JR, Mendes LC, Borges AS. Pneumonia causada pelo Rhodococcus equi.. Revista de Educação Continuada em Medicina Veterinária e Zootecnia do CRMV-SP 2002;5(1):73–86.
    doi: 10.36440/recmvz.v5i1.3285google scholar: lookup
  42. Prescott JF. Rhodococcus equi: an animal and human pathogen.. Clin Microbiol Rev 1991 Jan;4(1):20-34.
    doi: 10.1128/CMR.4.1.20pmc: PMC358176pubmed: 2004346google scholar: lookup
  43. Rakowska A, Marciniak-Karcz A, Bereznowski A, Cywińska A, Żychska M, Witkowski L. Less Typical Courses of Rhodococcus equi Infections in Foals.. Vet Sci 2022 Oct 31;9(11).
    doi: 10.3390/vetsci9110605pmc: PMC9698102pubmed: 36356082google scholar: lookup
  44. Reuss SM, Chaffin MK, Cohen ND. Extrapulmonary disorders associated with Rhodococcus equi infection in foals: 150 cases (1987-2007).. J Am Vet Med Assoc 2009 Oct 1;235(7):855-63.
    doi: 10.2460/javma.235.7.855pubmed: 19793018google scholar: lookup
  45. Riesenberg A, Feßler AT, Erol E, Prenger-Berninghoff E, Stamm I, Böse R, Heusinger A, Klarmann D, Werckenthin C, Schwarz S. MICs of 32 antimicrobial agents for Rhodococcus equi isolates of animal origin.. J Antimicrob Chemother 2014 Apr;69(4):1045-9.
    doi: 10.1093/jac/dkt460pubmed: 24275117google scholar: lookup
  46. Suarez-Mier G, Giguère S, Lee EA. Pulmonary disposition of erythromycin, azithromycin, and clarithromycin in foals.. J Vet Pharmacol Ther 2007 Apr;30(2):109-15.
  47. Sweeney CR, Sweeney RW, Divers TJ. Rhodococcus equi pneumonia in 48 foals: response to antimicrobial therapy.. Vet Microbiol 1987 Aug;14(3):329-36.
    doi: 10.1016/0378-1135(87)90120-9pubmed: 3672875google scholar: lookup
  48. Takai S. Epidemiology of Rhodococcus equi infections: a review.. Vet Microbiol 1997 Jun 16;56(3-4):167-76.
    doi: 10.1016/s0378-1135(97)00085-0pubmed: 9226831google scholar: lookup
  49. Takai S, Sasaki Y, Tsubaki S. Rhodococcus equi infection in Foals. Current concepts and implication for Future Research.. J Equine Sci 1995;6(4):105–119.
    doi: 10.1294/jes.6.105google scholar: lookup
  50. Vázquez-Boland JA, Giguère S, Hapeshi A, MacArthur I, Anastasi E, Valero-Rello A. Rhodococcus equi: the many facets of a pathogenic actinomycete.. Vet Microbiol 2013 Nov 29;167(1-2):9-33.
    doi: 10.1016/j.vetmic.2013.06.016pubmed: 23993705google scholar: lookup
  51. Vivrette SL, Sellon DC, Gibbons DS. Clinical application of a polymerase chain reaction assay in the diagnosis of pneumonia caused by Rhodococcus equi in a horse.. J Am Vet Med Assoc 2000 Nov 1;217(9):1348-50.
    doi: 10.2460/javma.2000.217.1348pubmed: 11061388google scholar: lookup
  52. Willingham-Lane JM, Berghaus LJ, Giguère S, Hondalus MK. Influence of Plasmid Type on the Replication of Rhodococcus equi in Host Macrophages.. mSphere 2016 Sep-Oct;1(5).
    doi: 10.1128/mSphere.00186-16pmc: PMC5061997pubmed: 27747295google scholar: lookup
  53. Yager JA. The pathogenesis of Rhodococcus equi pneumonia in foals.. Vet Microbiol 1987 Aug;14(3):225-32.
    doi: 10.1016/0378-1135(87)90109-xpubmed: 3314108google scholar: lookup

Citations

This article has been cited 0 times.